Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty

다국어 초록 (Multilingual Abstract)

Study Design: This was a retrospective clinical study.
Purpose: This study aimed to evaluate the effect of combination therapy with zoledronic acid and teriparatide on the risk of new vertebral fracture (NVF) in type 2 diabetes mellitus (T2DM) patients after percutaneous kyphoplasty (PKP).
Overview of Literature: Although T2DM had been associated with bone fragility and increased fracture risk, it remains unknown whether patients with T2DM could expect similar benefit from the combination therapy with zoledronic acid and teriparatide following PKP.
Methods: Total 106 diabetic patients who had undergone PKP and had received anti-osteoporosis treatment for osteoporotic vertebral compression fracture were enrolled and allocated into the following two groups: group I (n=52, zoledronic acid) and group II (n=54, zoledronic acid plus teriparatide). The operating time, bone cement volume, and complications related to anti-osteoporosis treatment or PKP, if any, were recorded. The Visual Analog Scale (VAS) score and Oswestry Disability Index (ODI) were assessed at admission, at discharge, and at the final follow-up. Dual-energy X-ray absorptiometry scan of the hip for the measurement of the bone mineral density (BMD) was performed preoperatively and at the final follow-up for all the patients.
Results: There was no significant difference in the age, body mass index, bone cement volume, or follow-up time of the groups. The mean follow-up duration was 22.5±1.6 months. All the patients had improved VAS and ODI, and group II had significantly better clinical outcomes than group I. All the patients had increased BMD at the latest follow-up, while group II exhibited significantly more improvement. The prevalence of NVF was lower in group II (11.5% vs. 7.4%, p=0.523). Male patients had a higher prevalence of NVF although the difference was not statistically significant.
Conclusions: Combination therapy with zoledronic acid and teriparatide could improve the clinical outcomes, and BMD and had the potential to reduce NVF in diabetic patients following PKP.

참고문헌 (Reference)

1 Zhang J, "Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women" 30 : 1475-1480, 2019

2 Koromani F, "Vertebral fractures in individuals with type 2 diabetes : more than skeletal complications alone" 43 : 137-144, 2020

3 Nilsson AG, "Type 2diabetes mellitus is associated with better bone microarchitecture but lower bone material strength and poorer physical function in elderly women : a population-based study" 32 : 1062-1071, 2017

4 Boonen S, "Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis" 27 : 1487-1493, 2012

5 Black DM, "The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis" 349 : 1207-1215, 2003

6 Tsuchie H, "The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture" 34 : 86-91, 2016

7 Orwoll ES, "The effect of teriparatide [human parathyroid hormone(1-34)]therapy on bone density in men with osteoporosis" 18 : 9-17, 2003

8 Kaufman JM, "Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis : treatment and discontinuation of therapy" 16 : 510-516, 2005

9 Schafer AL, "Six months of parathyroid Hormone(1-84)administered concurrently versus sequentially with monthly ibandronate over two years : the PTH and ibandronate combination study(PICS)randomized trial" 97 : 3522-3529, 2012

10 Wang L, "Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013" 317 : 2515-2523, 2017

11 Xu Y, "Prevalence and control of diabetes in Chinese adults" 310 : 948-959, 2013

12 Kanazawa I, "Osteoporosis and vertebral fracture are associated with deterioration of activities of daily living and quality of life in patients with type 2 diabetes mellitus" 37 : 503-511, 2019

13 Boonen S, "Onceyearly zoledronic acid in older men compared with women with recent hip fracture" 59 : 2084-2090, 2011

14 Cheng C, "New frontiers in osteoporosis therapy" 71 : 277-288, 2020

15 Bliuc D, "Mortality risk associated with lowtrauma osteoporotic fracture and subsequent fracture in men and women" 301 : 513-521, 2009

16 Liu JM, "Management of fracture risk in patients with diabetes : Chinese Expert Consensus" 11 : 906-919, 2019

17 Liu JT, "Long-term followup study of osteoporotic vertebral compression fracture treated using balloon kyphoplasty and vertebroplasty" 23 : 94-98, 2015

18 Patsch JM, "Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures" 28 : 313-324, 2013

19 Fribourg D, "Incidence of subsequent vertebral fracture after kyphoplasty" 29 : 2270-2276, 2004

20 Park SM, "Incidence and mortality of subsequent vertebral fractures : analysis of claims data of the Korea National Health Insurance Service from 2007 to 2016" 20 : 225-233, 2020

21 Boonen S, "Fracture risk and zoledronic acid therapy in men with osteoporosis" 367 : 1714-1723, 2012

22 Kasukawa Y, "Enhanced bone healing and decreased pain in sacral insufficiency fractures after teriparatide treatment : retrospective clinical-based observational study" 14 : 140-145, 2017

23 Barrionuevo P, "Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women : a network metaanalysis" 104 : 1623-1630, 2019

24 Cosman F, "Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis" 26 : 503-511, 2011

25 Min HK, "Effects of antiosteoporosis medications on radiological and clinical results after acute osteoporotic spinal fractures : a retrospective analysis of prospectively designed study" 30 : 2249-2256, 2019

26 Blasco J, "Effect of vertebroplasty on pain relief, quality of life, and the incidence of new vertebral fractures : a 12-month randomized follow-up, controlled trial" 27 : 1159-1166, 2012

27 Zeng LF, "Does routine antiosteoporosis medication lower the risk of fractures in male subjects? : an updated systematic review with meta-analysis of clinical trials" 10 : 882-, 2019

28 Heilmeier U, "Cortical bone laminar analysis reveals increased midcortical and periosteal porosity in type 2 diabetic postmenopausal women with history of fragility fractures compared to fracture-free diabetics" 27 : 2791-2802, 2016

29 Lou S, "Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis : a systematic review and meta-analysis of randomized controlled trials" 30 : 59-70, 2019

30 Boonen S, "Balloon kyphoplasty for the treatment of acute vertebral compression fractures : 2-year results from a randomized trial" 26 : 1627-1637, 2011

31 Lee DG, "Analysis of risk factors causing new symptomatic vertebral compression fractures after percutaneous vertebroplasty for painful osteoporotic vertebral compression fractures : a 4-year follow-up" 28 : E578-83, 2015